Tokyo, Japan & Boston, MA 9/25/17—Digital technology firm Konica Minolta has agreed to acquire Invicro, a CRO that also sells the VivoQuant and iPACS software for preclinical imaging. Invicro’s generates $106 million in annual revenues. Konica Minolta currently offers healthcare technologies, such as pathology products. Earlier this year, it acquired genetic testing firm Ambry Genetics. “Konica Minolta is the ideal partner to accelerate the impact of the informatics platform we have developed and deployed over the past decade,” commented Invicro co-founder and CEO Jack Hoppin. “The prospect of working with Konica Minolta and their recently acquired Ambry team on the translation of precision medicine innovations from research trials to clinical offerings is truly inspiring.” Invicro management will remain with the company. InVicro has more than 200 employees.

Although Invicro’s primary business is imaging services for discovery and clinical phase research, the company’s VivoQuant and iPACS software are used by labs for the analysis of in vivo animal imaging from MRI, PET, SPECT, CT and optical techniques. Among the providers of preclinical in vivo imaging systems are Bruker and PerkinElmer.